key: cord-0846173-nl3lke9z authors: Auletta, Jeffery J.; Adamson, Peter C.; Agin, Jonathan E.; Kearns, Pamela; Kennedy, Scott; Kieran, Mark W.; Ludwinski, Donna M.; Knox, Leona J.; McKay, Kristi; Rhiner, Pia; Thiele, Carol J.; Cripe, Timothy P. title: Pediatric cancer research: Surviving COVID‐19 date: 2020-06-18 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.28435 sha: 15f0baaecf1d428d45a770ed796d1a8ccb46f4cb doc_id: 846173 cord_uid: nl3lke9z A diverse panel of pediatric cancer advocates and experts, whose collective experience spans the continuum of international academic medicine, industry, government research, and cancer advocacy, recently discussed challenges for pediatric cancer research in the context of coronavirus disease 2019 (COVID‐19). Specifically, this special report addresses the following focus areas: (a) the critical role that translational research has played in transforming pediatric cancer outcomes; (b) the current and potential future impact of COVID‐19 on pediatric cancer research; (c) target areas of COVID‐19 research that may have application in immunity, oncogenesis, and therapeutic discovery; and (d) future considerations and directions in maintaining pediatric cancer research during and after COVID‐19. ing COVID-19 for patient advocacy groups and the charity sector include limited resources for patients and families mainly due to dramatically reduced philanthropic support, but also due to social restrictions affecting patient movement and lodging; reduced community engagement given direct effects of the pandemic on donor finances and health; and less government advocacy impact given its focus on the pandemic and its reallocating resources to address the pandemic (Table 2) . Importantly, industry has a vital role in supporting pediatric cancer research through drug discovery, laboratory research, and codevelopment of and support for clinical trials. Current challenges faced by industry include reduced available workforce, reallocation of resources to focus on assessment of pipelines for agents with potential value for COVID-19 patients, and contracted budgets for drug discovery (Table 3) . Significant morbidity and mortality secondary to COVID-19 infection have largely spared the pediatric population, including pediatric hematology, oncology, and hematopoietic cell transplant patients. 9 In general, immunocompetent pediatric patients with COVID-19 experience less severe disease than adult patients, 10 17 Decreases in regulatory T cells have also been linked with a hyperinflammatory response in adults, 18 requiring the use of monoclonal blocking antibodies like tocilizumab, an antiinterleukin 6 (IL-6) agent. 19 Interestingly, immune dysregulation and hyperinflammation as measured by whole blood transcription profiles have also been shown to correlate with severe respiratory syncytial virus (RSV) disease in infants, 20 who also have higher viral loads and more protracted viral decay than infants with mild RSV. 21 27 and adaptive immune responses. 28 As adults have a more proinflammatory background, they may be predisposed to more severe COVID-19 via a hyperinflammatory response to SARS-CoV-2. Adults and children also differ in their immune response to viral challenge. 29 Our knowledge about antimicrobial and anticancer responses continues to evolve, as we gain understanding for their common inflammatory cellular and molecular pathways. 36, 37 For example, type I IFNs have direct antiviral effects but also have key roles in antitumor immunity. 38 Furthermore, both cancer and infectious pathogens use similar strategies to avoid immune recognition. 39 Finally, chronic inflammation 40 and certain viral pathogens themselves promote oncogenesis. Therefore, immune profiling of SARS-CoV-2 infection may elucidate pathways involved in oncogenesis or inflammation that could be targeted with novel or repurposed cancer or supportive therapies. 41 Commonalities between antiviral and antitumor responses provide "silver linings" during the COVID-19 pandemic, given they could potentially foster and provide new directions for discovering therapies for cancer and COVID-19 (Table 4 ). For example, the BCR-ABL tyrosine kinase inhibitor, imatinib, revolutionized the treatment of Philadelphia-chromosome positive (Ph + ) acute lymphoblastic leukemia (ALL), such that allogeneic hematopoietic cell transplant in patients achieving molecular remission is no longer needed. 42 Given its development as an ABL kinase inhibitor, imatinib has been shown to block coronavirus membrane fusion, inhibiting viral entry into cells. 43 Similarly, the Janus kinase 1/2 inhibitor, ruxolitinib, and the blocking monoclonal IL-6 antibody, tocilizumab, may inhibit SARS-CoV-2-induced hyperinflammation 19 in addition to their use in steroid-refractory graft-versus-host disease following allogeneic hematopoietic cell transplant 44 and cytokine storm following chimeric antigen receptor T cell therapy, 45 respectively. Lastly, type I IFN, a key cytokine against viral infection and cancer, 46 is being explored as a potential therapy against COVID- 19. 47 Community respiratory viral infections are the most common type of infection in children. Given its high prevalence, high transmissibility, and lack of established therapeutic and preventative agents, SARS-CoV-2 will likely infect the majority of adults and children. Therefore, defining potential associations of SARS-CoV-2 with future cancer risk, especially in minority populations, 48 continue to impact many more millions of people, given the need to restructure life in response to an evolving pandemic. Adaptation to change requires flexibility in approaches for continuing pediatric oncology care and research, some of which may be carried forward given their potential longer term value as measured by improved efficiency, decreased burden to families, cost reduction, and ultimately new growth opportunities ( Table 5 ). The health crisis caused by COVID-19 warrants both scientific collaboration and reallocation of resources to contain its spread and to eradicate the disease entirely. However, other significant healthcare crises remain and potentially may be exacerbated by COVID-19, both directly by the virus itself or indirectly by the changes in life that the virus has caused. To this end, pediatric cancer remains the primary disease-related cause for mortality in children. Therefore, we must not lose focus on the need to continue to support, both scientifically and financially, research that is vital to discovering potential cures for pediatric cancer both to minimize the negative impact of COVID-19 and to leverage the lessons learned to make us better than before. Not fulfilling these missions jeopardizes the future of children with cancer, their families, and their communities. The authors would like to acknowledge all pediatric and adolescent and young adult (AYA) patients and families who have been touched by cancer and who inspire us as cancer clinicians and researchers and join us in the common pursuit in finding cures for all childhood cancers. We further acknowledge the additional layers of anxiety and complexity that COVID-19 has placed on them. Peter C. Adamson is an employee of Sanofi, which is studying treatments for patients with COVID-19 infection including vaccines, sarilumab, and hydroxychloroquine. All other authors declare that there is no conflict of interest. Jeffery J. Auletta https://orcid.org/0000-0002-1515-2141 Peter C. Adamson https://orcid.org/0000-0002-9487-757X Solving Kids' Cancer. The pandemic's impact on the pediatric cancer research landscape Acute lymphoblastic leukemia in children Cancer facts & figures 2020 Life expectancy of adult survivors of childhood cancer over 3 decades World Health Organization. Coronavirus disease (COVID-2019) situation reports Caring for patients with cancer in the COVID-19 era COVID-19: open letter to cancer researchers Cancer Research UK. Cancer Research UK response to government's charity package COVID-19 rapid guideline: children and young people who are immunocompromised Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China Severe outcomes among patients with coronavirus disease 2019 (COVID-19) -United States Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -United States CDC COVID-19 Response Team. Coronavirus disease 2019 in children-United States Viral dynamics in mild and severe cases of COVID-19 Risk of COVID-19 for patients with cancer Breadth of concomitant immune responses prior to patient recovery: a case report of nonsevere COVID-19 Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis COVID-19: consider cytokine storm syndromes and immunosuppression Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection Three hypotheses about children COVID19. Pediatr Paediatric Intensive Care Society. PICS statement regarding novel presentation of multi-system inflammatory disease COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr Concurrent respiratory viruses and Kawasaki disease A well infant with coronavirus disease 2019 (COVID-19) with high viral load Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly The full spectrum of human naive T cells The impact of differential antiviral immunity in children and adults Type I interferons in infectious disease Immunomodulatory functions of type I interferons Impaired type I interferon activity and exacerbated inflammatory response to in severe COVID-19 patients Type I IFN immunoprofiling in COVID-19 patients Immune profiles provide insights into respiratory syncytial virus disease severity in young children The trinity of COVID-19: immunity, inflammation and intervention Host immune response to infection and cancer: unexpected commonalities Inflammationinduced cancer: crosstalk between tumours, immune cells and microorganisms Type I interferons in anticancer immunity Immunogenic cell death in cancer and infectious disease Chronic inflammation in cancer development The immune landscape of cancer Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031 Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors How I treat steroid-refractory acute graft-versus-host disease Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' Type I interferon in chronic virus infection and cancer Compounds with therapeutic potential against novel respiratory 2019 coronavirus Characteristics and clinical outcomes of adult patients hospitalized with COVID-19-Georgia Are some ethnic groups more vulnerable to COVID-19 than others? Institute for Fiscal Studies In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer. 2020;e28435